JP2023524489A5 - - Google Patents

Info

Publication number
JP2023524489A5
JP2023524489A5 JP2022566330A JP2022566330A JP2023524489A5 JP 2023524489 A5 JP2023524489 A5 JP 2023524489A5 JP 2022566330 A JP2022566330 A JP 2022566330A JP 2022566330 A JP2022566330 A JP 2022566330A JP 2023524489 A5 JP2023524489 A5 JP 2023524489A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
pharmaceutically acceptable
substituted
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022566330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524489A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/091093 external-priority patent/WO2021219089A1/en
Publication of JP2023524489A publication Critical patent/JP2023524489A/ja
Publication of JP2023524489A5 publication Critical patent/JP2023524489A5/ja
Ceased legal-status Critical Current

Links

JP2022566330A 2020-04-30 2021-04-29 コロナウイルス感染症を処置するための共有結合修飾を有するｓａｒｓ－ｃｏｖ－２阻害剤 Ceased JP2023524489A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063017878P 2020-04-30 2020-04-30
US63/017,878 2020-04-30
US202063059095P 2020-07-30 2020-07-30
US63/059,095 2020-07-30
US202063112087P 2020-11-10 2020-11-10
US63/112,087 2020-11-10
PCT/CN2021/091093 WO2021219089A1 (en) 2020-04-30 2021-04-29 Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections

Publications (2)

Publication Number Publication Date
JP2023524489A JP2023524489A (ja) 2023-06-12
JP2023524489A5 true JP2023524489A5 (enExample) 2024-05-09

Family

ID=78373328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566330A Ceased JP2023524489A (ja) 2020-04-30 2021-04-29 コロナウイルス感染症を処置するための共有結合修飾を有するｓａｒｓ－ｃｏｖ－２阻害剤

Country Status (6)

Country Link
US (1) US20230174488A1 (enExample)
EP (1) EP4143176A4 (enExample)
JP (1) JP2023524489A (enExample)
CN (1) CN115803322B (enExample)
TW (1) TW202200551A (enExample)
WO (1) WO2021219089A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219089A1 (en) * 2020-04-30 2021-11-04 Insilico Medicine Ip Limited Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections
WO2022119756A1 (en) * 2020-12-04 2022-06-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection
WO2022221686A1 (en) * 2021-04-15 2022-10-20 Pardes Biosciences, Inc. Inhibitors of cysteine proteases and methods of use thereof
WO2023078238A1 (en) * 2021-11-02 2023-05-11 Insilico Medicine Ip Limited Sars-cov-2 inhibitors for treating coronavirus infections
JP2024542969A (ja) * 2021-11-02 2024-11-19 インシリコ メディシン アイピー リミテッド コロナウイルス感染を処置するためのｓａｒｓ－ｃｏｖ－２阻害剤
CN117143082B (zh) * 2022-03-07 2026-07-03 广州国家实验室 用作3c样蛋白酶抑制剂的氮杂双环[3.1.0]己烷衍生物
US20240158368A1 (en) 2022-10-14 2024-05-16 Abbvie Inc. Pyrrolidine Main Protease Inhibitors as Antiviral Agents
WO2024174966A1 (en) * 2023-02-20 2024-08-29 Insilico Medicine Ip Limited Mpro inhibitors for treating coronavirus infections
WO2024222796A1 (en) * 2023-04-26 2024-10-31 Insilico Medicine Ip Limited Crystalline sars-cov-2 inhibitor and uses thereof
WO2025067202A1 (en) * 2023-09-25 2025-04-03 Insilico Medicine Ip Limited 3cl-protease inhibitors for treating or preventing veterinary coronavirus infections
CN117756760B (zh) * 2024-01-10 2026-07-31 山东邹平大展新材料有限公司 一种2,3-二氢苯并呋喃的合成方法
CN118344285B (zh) * 2024-01-10 2025-06-06 中国药科大学 一类靶向SARS-Cov-2 3CLpro的化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
US9695133B2 (en) * 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
US9975885B2 (en) * 2016-04-28 2018-05-22 Purdue Research Foundation Broad-spectrum non-covalent coronavirus protease inhibitors
WO2021219089A1 (en) * 2020-04-30 2021-11-04 Insilico Medicine Ip Limited Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infections

Similar Documents

Publication Publication Date Title
KR102757890B1 (ko) 화합물, 조성물 및 방법
JP2024166311A (ja) 化合物、組成物、及び、方法
Turner et al. Antihypertensive thiadiazoles. 2. Vasodilator activity of some 2-aryl-5-guanidino-1, 3, 4-thiadiazoles
JP5576485B2 (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
ES2881776T3 (es) Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
ES2315566T3 (es) Tiazolidin-4-onas para inhibir proteinas hyak3.
US12091392B2 (en) Compounds, compositions and methods
JP2002524463A5 (enExample)
JP2023533447A5 (enExample)
CA3081386A1 (en) Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2008535903A5 (enExample)
JP2009535307A5 (enExample)
CA2806015A1 (en) N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein
NZ290404A (en) Distamycin a analogues; pharmaceutical compositions
JP2021519263A5 (enExample)
RU2008107733A (ru) Ингибиторы gsk-3
JP2007527919A5 (enExample)
JP2023504542A5 (enExample)
JP2007523957A (ja) 新規化学化合物
JP2021514399A5 (enExample)
ES2657942T3 (es) Compuestos de metanotiona que tienen actividad antiviral
JP5474820B2 (ja) アルテミシニンの二量体誘導体、および抗癌療法における用途
JP2022521474A5 (enExample)
US12606526B2 (en) Substituted salicylamide compounds and use thereof
JP2024540477A5 (enExample)